Important Notice Regarding Prexige® Class Action
On November 8, 2007, Connie Singh and Cheryl Lundringan (the “Plaintiffs”) commenced a proposed class proceeding against Novartis Pharmaceuticals Canada Inc., Novartis Consumer Health Canada Inc., Novartis Pharma Services AG, and Novartis Pharma AG (the “Defendants”) alleging that Prexige®, a prescription drug marketed by the Defendants, caused liver damage, kidney dysfunction, and other unspecified medical problems. The Defendants deny all of the allegations made against them in the claim.
As the matter has not advanced since the claim was filed, and the Plaintiffs do not intend to continue pursuing the claim, the Ontario Superior Court of Justice has ordered that the proceeding be dismissed pursuant to s. 29.1 of the Class Proceedings Act, 1992 effective on December 9, 2021.
YOU SHOULD TAKE NOTICE THAT while this proposed class action was pending, limitation periods (time limits) for starting individual actions in Ontario against the Defendants were suspended. Those limitation periods will begin recommence running as of December 9, 2021. Upon the expiry of a limitation period, you may lose your right to sue. If you wish to pursue your own action against the Defendants, you should consult with your own lawyer, as you may need to take steps to protect your rights.
If you have any questions about any of the information in this notice, please contact Merchant Law Group https://www.merchantlaw.com
This notice has been approved by the Ontario Superior Court of Justice.